UW Health recruiting volunteers for clinical trial of new Alzheimer’s drug
UW Health is recruiting volunteers for a clinical trial to test a new Alzheimer's drug recently approved by the FDA....
UW Health is recruiting volunteers for a clinical trial to test a new Alzheimer's drug recently approved by the FDA....
Feedback on the FDA's draft guidance on psychedelic research is mostly positive, but concerns arise around two-monitor recommendation....
The Food and Drug Administration has fully approved the first drug shown to slow down Alzheimer's disease....
The FDA is expected to approve the first drug to show promise of slowing the progression of Alzheimer’s disease. But while patient advocates are celebrating, some critics predict the rollout of the drug will aggravate racial disparities in elder care....
The much-anticipated draft guidance on DCTs is here, however, it might have missed several important points on delegation and data management....
The first drug fully generated by artificial intelligence entered clinical trials with human patients this week. The drug was created as a treatment for idiopathic pulmonary fibrosis, a chronic lung disease....
The first targeted drug developed specifically for people with brain cancer has shown promise as a treatment for tumors called low-grade gliomas....
The first drug shown to slow down Alzheimer's disease is likely to receive full approval from the Food and Drug Administration by July 6....
The U.S. Food and Drug Administration published a new draft guidance to highlight fundamental considerations to researchers investigating the use of psychedelic drugs for potential treatment of medical conditions, including psychiatric or substance use disorders....
After decades of limited success, scientists say research has reached a turning point, with many predicting more cancer vaccines will be out in five years....